News and Events

Primary tabs

Industry News

Switzerland Receives Request For Compulsory Licence On Breast Cancer Drug

Swiss health activist group Public Eye yesterday requested the Swiss government to declare a compulsory licence for a Roche breast cancer treatment which the group says is unaffordable.

Industry News

US Congressional Watchdog Launches Team For Sci/Tech Analysis

A new chapter begins. The business of technology and science has been, and will increasingly be, the business of government: with this in mind, the US Government Accountability Office (GAO) has launched a new Science, Technology Assessment and Analytics (STTA) team with the aim to expand the support to lawmakers on topics whose importance has exponentially increased in the world of today.

Industry News

WIPO Sheds Light On Artificial Intelligence Patenting Trends In New Report

The World Intellectual Property Organization today released its first report on artificial intelligence showing a sharp rise in patenting activities over the last few years. WIPO Director General Francis Gurry called artificial intelligence a “game changer” during a press briefing yesterday and said WIPO hopes to spark a conversation on the issue among its member states this year. As in most other fields, leading patent offices are the United States and China.

Industry News

Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues

Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly.

Industry News

WHO Member States Call For Transparency, Access To Innovation On Cancer Drug Pricing

A substantive discussion took place at the World Health Organization Executive Board meeting yesterday in response to a recently released WHO report on cancer drug pricing. Among the variety of perspectives expressed, many formed consensus in calling for increased transparency of research and development (R&D) costs and equitable access to innovative cancer drugs.

Industry News

WHO Holds Discussions On Roadmap For Improving Access To Medicines

Unaffordable prices, unavailable medicines, a rising need for accessible noncommunicable diseases treatments – these set the stage as the World Health Organization Executive Board started discussion today on one of the more contentious issues of the week. For the Board’s approval is in particular a roadmap and action plan including a dual strategy based on safety and efficacy of health products, and their affordability.

Industry News

DNDi, MMV Make 400 Compounds Available To Boost Pandemic Disease Research

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) today announced the launch of the “Pandemic Response Box”, which offers researchers open access to 400 compounds that could lead to development of new treatments for pandemic diseases. In return, researchers “will be expected to share data resulting from research on the […]

Industry News

Measuring Outputs Seen As Key To WHO Transformation

Measurable outputs are a key element of the World Health Organization transformation and its “triple billion” target. Last week, WHO Executive Board discussed the Impact Framework, a key measurement system. Board members asked clarifications on indicators and underlined the challenge of data collection in many countries. A consultation with country experts is expected to be held before the May World Health Assembly.

Industry News

WHO Draft Resolution On Universal Health Coverage Shows Efforts At Consensus

With half the world’s population still lacking access to essential health services, World Health Organization Executive Board members this week are working to agree on a resolution indicating ways through which this situation can be alleviated. Discussions are going on outside plenary room as delegates seek agreement on a draft resolution.

Industry News

Inside Views: WHO’s Access Roadmap And The Art Of Accommodation Of Pharma Interest

The Roadmap to access to medicines, vaccines and other health products (Roadmap) to be discussed at this week's 144th session of WHO’s Executive Board accommodates vital interest of pharmaceutical TNCs on critical issues such as the approach to access, technical assistance on the use of TRIPS flexibilities and access to biosimilars.

Adoption of the Roadmap in its current form very well accommodates the interest of the Pharmaceutical TNCs and therefore one need not expect any proactive steps by WHO towards promoting access after the adoption of the Roadmap.